"Sarepta may will take the attitude that if you can't beat 'em, join 'em..."
Wayne,
They have no choice but to "join 'em"
In the background there are 2 more problems for Sarepta management....
They have Tier 1 funds on their register. You can imagine the agitation going on behind closed doors with the likes of Fidelity looking after it's investment.
"You spent how much $$$ on Gene Therapy R&D...and the results are what...?
Market cap has halved and confidence in the "unlucky randomization" excuse for its GT failure is zero. Even with 25% additional dystrophin, muscle function did not improve.
Then, Doug Ingram has to manage Roche deal...will Roche ask any of the $1.3B be returned?
Right now, Sarepta lawyers are googling what "variation by conduct" means.
They should never have used "unlucky randomization" as an excuse - they're in deep poo!
